On Friday, WPCS International Incorporated (NASDAQ:WPCS)’s shares declined -13.21% to $0.23, while its weekly performance remained better, showing an upward trend up to 27.78%.
Recently, WPCS International, declared that its domestic operation was awarded $14.4 million in new contracts during the month of March 2015.
Sebastian Giordano, Interim CEO of WPCS, commented, “While we continue our corporate restructuring efforts, we are extremely happy to see our core Suisun City business continue to capitalize upon its stellar reputation as a leading provider of low voltage and structured building communications cabling.”
The two San Francisco-based structured, low voltage communications cabling and installation projects comprise an $8.4 million contract for the California Pacific Medical Center, Cathedral Hills, a new 274-bed hospital and a $4.5 million contract for the Trans Bay Center Project, a visionary and transformational transportation and housing project that, once accomplished, will be the tallest structure in San Francisco. In addition, WPCS was also awarded $1.5 million in new work from existing customers.
WPCS International Incorporated provides low voltage communication infrastructure services in the public services, healthcare, energy, and corporate enterprise markets worldwide. The company creates integrated building systems, counting the installation of structured cabling systems; and develops networks for customer’s wireless communication requirements comprising Wi-Fi networks, point-to-point systems, cellular networks, in-building systems, and two-way communication systems, in addition to integrates telecommunications, life safety, environmental controls, security, and HVAC systems.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)’s shares gained 0.71% to $19.92, during the last trading session on Friday, hitting its highest level, while its weekly performance remained better, showing an upward trend up to 27.12%.
Sucampo Pharmaceuticals, will webcast its corporate presentation at the 14th Annual Needham Healthcare Conference taking place April 14, 2015 at 1:40 PM ET.
Investors interested in arranging a meeting with the Company’s administration during this conference should contact the conference coordinator.
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs in the Americas, Europe, and Asia. It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders, in addition to other therapeutic applications of drug technologies.
At the end of Friday’s trade, Sysorex Global Holdings Corp. (NASDAQ:SYRX)’s shares dipped -1.94% to $1.52, while its weekly performance remained better, showing an upward trend up to 26.67%.
Sysorex, been awarded a contract in the National Aeronautics and Space Administration’s (NASA) fifth Solutions for Enterprise-Wide Procurement (SEWP) contract vehicle. Sysorex received the contract award as part of the small business group otherwise known as “Group C”. The new vehicle has a maximum value of $20 billion with a base period of 5 years and one 5 year option period.
Ali noted that Sysorex’s long-time partnerships and deep experience with leading technology vendors and OEMs allows it to offer a broad variety of state-of-the-art solutions in addition to noteworthy cost savings to customers across the federal spectrum.
The SEWP V contract is Sysorex’s second federal government win in the past month. In March the company was awarded a subcontract on the $249 million Enterprise Information Technology Services (EITS) Indefinite Delivery / Indefinite Quantity (ID/IQ) contract in support of the U.S. Army Program Executive Office for Enterprise Information Systems (PEO-EIS).
Sysorex Global Holdings Corp., through its auxiliaries, provides data analytics and location based solutions and services to commercial and government customers worldwide. It operates through four segments: IT Commercial, IT Government, eSolutions, and Location-Based Technology.
Advaxis, Inc. (NASDAQ:ADXS), ended its Friday’s trading session with 4.56% gain, and closed at $19.73, hitting its highest level, while its weekly performance remained better, showing an upward trend up to 26.07%.
Recently, Advaxis declared that its stock has been added to the Loncar Cancer Immunotherapy Index (LCINDX). Based on current allocations and current share prices, Advaxis is the most heavily weighted stock in LCINDX.
The Loncar Cancer Immunotherapy Index (LCINDX), produced by Loncar Investments, LLC, is the first professional index to track the transformational immunotherapy field within the biotechnology space. LCINDX seeks to track the performance of a basket of companies that develops therapies to treat cancer by harnessing the body’s own immune system. The index will provide a metric to follow its progress as researchers advance new technologies for the benefit of patients who fight cancer disease. LCINDX is an index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in immunotherapy.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
